Cargando…

Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity

Isoforms of protein kinase Akt are involved in essential processes including cell proliferation, survival, and metabolism. However, their individual roles in health and disease have not been thoroughly evaluated. Thus, there is an urgent need for perturbation studies, preferably mediated by highly s...

Descripción completa

Detalles Bibliográficos
Autores principales: Quambusch, Lena, Landel, Ina, Depta, Laura, Weisner, Jörn, Uhlenbrock, Niklas, Müller, Matthias P., Glanemann, Franziska, Althoff, Kristina, Siveke, Jens T., Rauh, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972997/
https://www.ncbi.nlm.nih.gov/pubmed/31584233
http://dx.doi.org/10.1002/anie.201909857
_version_ 1783489952566214656
author Quambusch, Lena
Landel, Ina
Depta, Laura
Weisner, Jörn
Uhlenbrock, Niklas
Müller, Matthias P.
Glanemann, Franziska
Althoff, Kristina
Siveke, Jens T.
Rauh, Daniel
author_facet Quambusch, Lena
Landel, Ina
Depta, Laura
Weisner, Jörn
Uhlenbrock, Niklas
Müller, Matthias P.
Glanemann, Franziska
Althoff, Kristina
Siveke, Jens T.
Rauh, Daniel
author_sort Quambusch, Lena
collection PubMed
description Isoforms of protein kinase Akt are involved in essential processes including cell proliferation, survival, and metabolism. However, their individual roles in health and disease have not been thoroughly evaluated. Thus, there is an urgent need for perturbation studies, preferably mediated by highly selective bioactive small molecules. Herein, we present a structure‐guided approach for the design of structurally diverse and pharmacologically beneficial covalent‐allosteric modifiers, which enabled an investigation of the isoform‐specific preferences and the important residues within the allosteric site of the different isoforms. The biochemical, cellular, and structural evaluations revealed interactions responsible for the selective binding profiles. The isoform‐selective covalent‐allosteric Akt inhibitors that emerged from this approach showed a conclusive structure–activity relationship and broke ground in the development of selective probes to delineate the isoform‐specific functions of Akt kinases.
format Online
Article
Text
id pubmed-6972997
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69729972020-01-27 Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity Quambusch, Lena Landel, Ina Depta, Laura Weisner, Jörn Uhlenbrock, Niklas Müller, Matthias P. Glanemann, Franziska Althoff, Kristina Siveke, Jens T. Rauh, Daniel Angew Chem Int Ed Engl Communications Isoforms of protein kinase Akt are involved in essential processes including cell proliferation, survival, and metabolism. However, their individual roles in health and disease have not been thoroughly evaluated. Thus, there is an urgent need for perturbation studies, preferably mediated by highly selective bioactive small molecules. Herein, we present a structure‐guided approach for the design of structurally diverse and pharmacologically beneficial covalent‐allosteric modifiers, which enabled an investigation of the isoform‐specific preferences and the important residues within the allosteric site of the different isoforms. The biochemical, cellular, and structural evaluations revealed interactions responsible for the selective binding profiles. The isoform‐selective covalent‐allosteric Akt inhibitors that emerged from this approach showed a conclusive structure–activity relationship and broke ground in the development of selective probes to delineate the isoform‐specific functions of Akt kinases. John Wiley and Sons Inc. 2019-11-08 2019-12-19 /pmc/articles/PMC6972997/ /pubmed/31584233 http://dx.doi.org/10.1002/anie.201909857 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Communications
Quambusch, Lena
Landel, Ina
Depta, Laura
Weisner, Jörn
Uhlenbrock, Niklas
Müller, Matthias P.
Glanemann, Franziska
Althoff, Kristina
Siveke, Jens T.
Rauh, Daniel
Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
title Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
title_full Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
title_fullStr Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
title_full_unstemmed Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
title_short Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
title_sort covalent‐allosteric inhibitors to achieve akt isoform‐selectivity
topic Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972997/
https://www.ncbi.nlm.nih.gov/pubmed/31584233
http://dx.doi.org/10.1002/anie.201909857
work_keys_str_mv AT quambuschlena covalentallostericinhibitorstoachieveaktisoformselectivity
AT landelina covalentallostericinhibitorstoachieveaktisoformselectivity
AT deptalaura covalentallostericinhibitorstoachieveaktisoformselectivity
AT weisnerjorn covalentallostericinhibitorstoachieveaktisoformselectivity
AT uhlenbrockniklas covalentallostericinhibitorstoachieveaktisoformselectivity
AT mullermatthiasp covalentallostericinhibitorstoachieveaktisoformselectivity
AT glanemannfranziska covalentallostericinhibitorstoachieveaktisoformselectivity
AT althoffkristina covalentallostericinhibitorstoachieveaktisoformselectivity
AT sivekejenst covalentallostericinhibitorstoachieveaktisoformselectivity
AT rauhdaniel covalentallostericinhibitorstoachieveaktisoformselectivity